새로 개발되고 있는 B형간염 치료법 = New Potential Therapies for Chronic Hepatitis B

다국어 초록 (Multilingual Abstract)

A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective in inhibiting HBV replication but rarely achieve HBsAg clearance. The present article introduces a new definition of HBV cure and several emerging therapies for HBV cure, including direct acting antivirals and immune modulatory antivirals.

참고문헌 (Reference)

1 Flisiak R, "siRNA drug development against hepatitis B virus infection" 18 : 609-617, 2018

2 Lee HM, "Updates on chronic HBV: current challenges and future goals" 17 : 271-291, 2019

3 Bazinet M, "Update on safety and efficacy in the REP 401 protocol : REP 2139-Mgor REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon lpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection" 66 : S688-S699, 2017

4 Likhitsup A, "Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials" 23 : 401-416, 2019

5 Bogomolov P, "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B : first results of a phase Ib/IIa study" 65 : 490-498, 2016

6 Hynes RO, "Toward responsible human genome editing" 317 : 1829-1830, 2017

7 Wedemeyer H, "Therapeutic vaccination of chronic hepatitis B patients with ABX203(NASVAC)to prevent relapse after stopping NUCs : contrasting timing rebound between tenofovir and entecavir" 66 : S101-, 2017

8 Gane EJ, "The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection" 63 : 320-328, 2015

9 Boni C, "TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues" 154 : 1764-1777, 2018

10 Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA" 343 : 1221-1228, 2014

11 Janssen HLA, "Safety, efficacy and pharmacodynamics of vesatolimod(GS-9620)in virally suppressed patients with chronic hepatitis B" 68 : 431-440, 2018

12 Al-Mahtab M, "Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection" 11 : e0156667-, 2016

13 Lok AS, "Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B" 65 : 509-516, 2016

14 Liang TJ, "Present and future therapies of hepatitis B : from discovery to cure" 62 : 1893-1908, 2015

15 Pei Y, "Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection" 60 : 6461-6479, 2017

16 Koh S, "Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3" 155 : 180-193, 2018

17 Javanbakht H, "Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo" 11 : 441-454, 2018

18 Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B" 대한간학회 25 (25): 93-159, 2019

19 Wang XJ, "Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity" 120 : 140-146, 2015

20 Cai D, "Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation" 56 : 4277-4288, 2012

21 Belloni L, "IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome" 122 : 529-537, 2012

22 Lok AS, "Hepatitis B cure : from discovery to regulatory approval" 66 : 1296-1313, 2017

23 "Global hepatitis report" World Health Organization

24 Lanford RE, "GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees" 144 : 1508-1517, 2013

25 Blank A, "First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B" 65 : 483-489, 2016

26 Ren Q, "Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate(GLS4)" 25 : 1042-1056, 2017

27 Höner Zu Siederdissen C, "Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients" 218 : 1480-1484, 2018

28 Seeger C, "Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA" 24 : 1258-1266, 2016

29 Boni C, "Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis" 157 : 227-241, 2019

30 Brezillon N, "Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice" 6 : e25096-, 2011

31 Rao M, "Anti-PD-1/PD-L1 therapy for infectious diseases : learning from the cancer paradigm" 56 : 221-228, 2017

32 Moyo B, "Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus" 244 : 311-320, 2018

33 Streinu-Cercel A, "A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B" 66 : S688-S689, 2017

34 Revill PA, "A global scientific strategy to cure hepatitis B" 4 : 545-558, 2019